XBI SPDR S&P Biotech ETF
- 89.680
- +1.540+1.75%
Twist Bioscience Launches MGF Product, Stock Climbs 10%
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 27.7% on an annualized basis producing an average annual return of 40.43%. Currently, Moderna has a market capitalization of
Twist Bioscience Shares Are Trading Higher After the Company Announced the Launch of Twist Multiplexed Gene Fragments.
Twist Bioscience Shares Are Trading Higher After the Company Announced the Launch of Twist Multiplexed Gene Fragments.
HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $44 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $44 price target.
Top ETFs With the Most and Least Options Activity - Barclays
JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target
JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and maintains $80 price target.
Crinetics Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 66.42% JMP Securities → $80 Reiterates Market Outperform → Market Outperform 05/07/2024 101.79%
Novavax Hits a 52-week High as Sanofi Deal Prompts J.P. Morgan Upgrade
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
The Food and Drug Administration (FDA) notified Moderna Inc (NASDAQ:MRNA) on Friday that its review of a new vaccine has been delayed.
FDA Has Has Informed Moderna That Due To Administrative Constraints, It Will Not Complete Its Review Of MRNA-1345 By The PDUFA Date Of May 12
FDA Has Has Informed Moderna That Due To Administrative Constraints, It Will Not Complete Its Review Of MRNA-1345 By The PDUFA Date Of May 12
The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...
① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.
Crinetics Pharmaceuticals Q1 2024 GAAP EPS $(0.93) Misses $(0.81) Estimate, Sales $640.000K Beat $255.556K Estimate
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.81) by 14.81 percent. This is a 9.41 percent decrease over los
Alpine Immune Sciences Q1 EPS $(0.28) Beats $(0.41) Estimate, Sales $7.03M Beat $3.52M Estimate
Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.41) by 31.71 percent. This is unchanged from the same period last y
10 Health Care Stocks With Whale Alerts In Today's Session
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Editas Medicine Upgraded at J.P. Morgan on Recent Weakness
Trade Desk To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Baird raise
Mizuho Maintains Neutral on Amgen, Raises Price Target to $235
Mizuho analyst Salim Syed maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $223 to $235.
Amgen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 -23.57% Mizuho $223 → $235 Maintains Neutral 05/03/2024 6.67% RBC Capital $332 → $328 Maintains
Revolution Medicines Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 20.07% Needham → $46 Reiterates Buy → Buy 04/12/2024 17.46% Oppenheimer $43 → $45 Maintains Out